反応式
[Cl:1][C:2]1[C:7]([C:8]([F:11])([F:10])[F:9])=[CH:6][CH:5]=[CH:4][C:3]=1[C:12]([N:14]1[CH2:19][CH2:18][N:17]2[C:20]([C:23]3[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=3)=[N:21][N:22]=[C:16]2[CH2:15]1)=[O:13].[F:29]C1C=CC(B(O)O)=CC=1.C1(B(O)O)C=CC=CC=1.CCCC(C)C>>[Cl:1][C:2]1[C:7]([C:8]([F:10])([F:9])[F:11])=[CH:6][CH:5]=[CH:4][C:3]=1[C:12]([N:14]1[CH2:19][CH2:18][N:17]2[C:20]([C:23]3[CH:28]=[CH:27][C:26]([F:29])=[CH:25][CH:24]=3)=[N:21][N:22]=[C:16]2[CH2:15]1)=[O:13]参加物
5
反応物 4
生成物 1
実験手順
7-{[2-chloro-3-(trifluoromethyl)phenyl]carbonyl}-3-(4-fluorophenyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine was prepared in a manner analogous to that described above for 7-{[2-chloro-3-(trifluoromethyl)phenyl]carbonyl}-3-phenyl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine (Example 13), but using (4-fluorophenyl)boronic acid (commercially available e.g. from Alfa Aesar or ABCR) in the place of phenylboronic acid, and using MDAP followed by isohexane trituration rather than MDAP.
出典と根拠
- ORDレコード
- ord-563509871d2442728096bbab9e7a54c6
- 出典データセット
- uspto-grants-2013_08
- 特許番号
- US08501946B2
関連ノート
読み込み中…